Arrowhead Signs Exclusive License Agreement with Madrigal for ARO-PNPLA3
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 05 2026
0mins
Arrowhead Pharmaceuticals (ARWR) announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (MDGL) for ARO-PNPLA3, Arrowhead's clinical stage RNA interference therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 as a potential treatment for patients with metabolic dysfunction-associated steatohepatitis. PNPLA3 has strong genetic and preclinical validation as a driver of fat accumulation and damage in the livers of patients who carry the I148M mutation. The I148M genetic variant is involved with the underlying pathophysiology and is a known risk factor for hepatic steatosis, steatohepatitis, elevated plasma liver enzyme levels, hepatic fibrosis, and cirrhosis.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARWR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARWR
Wall Street analysts forecast ARWR stock price to rise
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 75.540
Low
35.00
Averages
82.00
High
110.00
Current: 75.540
Low
35.00
Averages
82.00
High
110.00
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cardiovascular Disease Costs Set to Skyrocket, Urgent Need for AI Solutions
- Rising Cardiovascular Costs: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment strategies for cardiac patients, thereby driving structural changes in the healthcare industry.
- Rapid Growth of AI Cardiology Market: The global AI cardiology market is projected to grow from $2.78 billion this year to over $14 billion by 2034, reflecting a strong demand for innovative technologies as health systems rush to deploy machine learning tools to address diagnostic backlogs.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform at the AEPC conference in Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI without the need for expensive machines and long wait times.
- International Collaborations and Market Expansion: VentriPoint has established partnerships for regulatory approval of VMS+™ 4.0 in China and is promoting cardiac diagnostics in Costa Rica and Indigenous communities in Canada, demonstrating its potential for global market expansion and commercial momentum.
See More
Cardiovascular Disease Costs Surge, AI Technology Becomes Key
- Cost Warning for Cardiovascular Disease: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment approaches for cardiac patients, potentially leading to significant industry transformation.
- Growth of AI Cardiology Market: The global AI cardiology market is valued at $2.78 billion this year and is projected to exceed $14 billion by 2034, driving health systems to accelerate the deployment of machine learning tools to address diagnostic backlogs, thereby enhancing medical efficiency and patient satisfaction.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform, VMS+™ 4.0, at the AEPC annual meeting in Italy, which can convert standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI while significantly reducing equipment costs and wait times.
- International Collaborations and Market Expansion: VentriPoint has established relationships with multiple international partners, including Lishman Global, which is applying for regulatory approval in China, and collaborations in Costa Rica and Indigenous communities in Canada, demonstrating its growth potential and strategic positioning in the global cardiac diagnostics market.
See More
Arrowhead Pharmaceuticals Q2 2026 Earnings Call Highlights
- Prescription Growth: Arrowhead Pharmaceuticals has written over 400 prescriptions since the launch of REDEMPLO, with approximately 30 new prescriptions each week, indicating strong market demand and product acceptance, which is expected to drive future revenue growth.
- Pricing Strategy Adjustment: The U.S. wholesale acquisition cost for REDEMPLO has been reduced from $60,000 to $45,000 per year, aimed at expanding market coverage, particularly for patients with high triglycerides, potentially enhancing market share and competitiveness.
- Strong Financial Position: As of March 31, 2026, Arrowhead reported nearly $1.8 billion in cash and investments, demonstrating robust financial strength to support future R&D and market expansion plans.
- Clinical Trial Progress: Top-line data from the SHASTA-3 and SHASTA-4 studies are expected to be released in Q3, with plans to file a supplemental new drug application with the FDA by the end of 2026, which could provide new growth momentum for the company.
See More
Arrowhead Pharmaceuticals to Participate in Multiple Upcoming Conferences
- Conference Schedule: Arrowhead Pharmaceuticals is set to participate in the BofA Securities 2026 Healthcare Conference from May 12-14, 2026, featuring an investor group dinner and a fireside chat presentation, showcasing its latest advancements in RNA interference.
- Key Presentations: At the TIDES USA conference, Arrowhead will present its systemic RNAi targeting MAPT on May 13 at 4:45 PM, highlighting its potential applications in the central nervous system, which is expected to attract investor interest.
- Clinical Research Showcase: During the European Atherosclerosis Society Congress, Arrowhead will discuss the pharmacokinetics and pharmacodynamics of Plozasiran in subjects with renal or hepatic impairment, underscoring its significance in treating complex diseases.
- Strategic Commitment: Arrowhead's participation not only demonstrates its influence in the global healthcare sector but also indicates its dedication to addressing unmet medical needs through innovative drug development, further solidifying its market position.
See More
Latest Wall Street Rating Updates
- Apple's Positive Outlook: Bank of America reiterates a buy rating on Apple, forecasting that iPhone revenues will exceed expectations in 2026 due to record upgraders and strong gross margins despite commodity pressures, indicating sustained competitiveness in the smartphone market.
- Roblox Demand Slowdown: Bank of America downgrades Roblox to neutral, citing a significant decline in platform demand; while acknowledging its ability to compress development costs, the uncertainty around the timeline for demand recovery may impact its market performance.
- CoreWeave Growth Potential: Citi reiterates CoreWeave as a buy, raising its price target from $126 to $155, estimating a quarterly growth of 35-40% in AI infrastructure, showcasing strong performance across a diversified customer base.
- Hershey's Positive Outlook: TD Cowen upgrades Hershey to buy, expressing confidence that the company will raise its 2026 guidance and return to volume growth in 2027, reflecting strong recovery potential in the confectionery market.
See More
REDEMPLO Approved in Australia for FCS Treatment
- First Approved Drug: REDEMPLO is the first medicine approved in Australia for the treatment of familial chylomicronemia syndrome (FCS), authorized for both genetically confirmed and clinically diagnosed adult patients, marking a significant breakthrough in this therapeutic area.
- Clinical Trial Results: In the Phase 3 PALISADE study, REDEMPLO achieved an 80% median reduction in triglycerides and significantly lowered the incidence of acute pancreatitis, demonstrating its potential to improve patients' quality of life.
- Global Expansion Strategy: This approval follows those in the U.S., Canada, and China, indicating Arrowhead Pharmaceuticals' commitment to expanding global treatment options for FCS patients and enhancing its market competitiveness.
- Innovative Treatment Method: REDEMPLO is administered via self-injection every three months, providing a convenient treatment option that is expected to significantly improve long-term health management and quality of life for FCS patients.
See More
Cardiovascular Disease Costs Set to Skyrocket, Urgent Need for AI Solutions
- Rising Cardiovascular Costs: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment strategies for cardiac patients, thereby driving structural changes in the healthcare industry.
- Rapid Growth of AI Cardiology Market: The global AI cardiology market is projected to grow from $2.78 billion this year to over $14 billion by 2034, reflecting a strong demand for innovative technologies as health systems rush to deploy machine learning tools to address diagnostic backlogs.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform at the AEPC conference in Italy, which converts standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI without the need for expensive machines and long wait times.
- International Collaborations and Market Expansion: VentriPoint has established partnerships for regulatory approval of VMS+™ 4.0 in China and is promoting cardiac diagnostics in Costa Rica and Indigenous communities in Canada, demonstrating its potential for global market expansion and commercial momentum.
See More
Cardiovascular Disease Costs Surge, AI Technology Becomes Key
- Cost Warning for Cardiovascular Disease: The American Heart Association warns that U.S. heart disease costs are set to quadruple by 2050, with national healthcare spending nearing $5 trillion, compelling hospitals to rethink their diagnostic and treatment approaches for cardiac patients, potentially leading to significant industry transformation.
- Growth of AI Cardiology Market: The global AI cardiology market is valued at $2.78 billion this year and is projected to exceed $14 billion by 2034, driving health systems to accelerate the deployment of machine learning tools to address diagnostic backlogs, thereby enhancing medical efficiency and patient satisfaction.
- Showcasing VMS+™ 4.0 Technology: VentriPoint Diagnostics will showcase its AI-powered cardiac imaging platform, VMS+™ 4.0, at the AEPC annual meeting in Italy, which can convert standard 2D ultrasound scans into detailed 3D heart models, providing results comparable to cardiac MRI while significantly reducing equipment costs and wait times.
- International Collaborations and Market Expansion: VentriPoint has established relationships with multiple international partners, including Lishman Global, which is applying for regulatory approval in China, and collaborations in Costa Rica and Indigenous communities in Canada, demonstrating its growth potential and strategic positioning in the global cardiac diagnostics market.
See More
Arrowhead Pharmaceuticals Q2 2026 Earnings Call Highlights
- Prescription Growth: Arrowhead Pharmaceuticals has written over 400 prescriptions since the launch of REDEMPLO, with approximately 30 new prescriptions each week, indicating strong market demand and product acceptance, which is expected to drive future revenue growth.
- Pricing Strategy Adjustment: The U.S. wholesale acquisition cost for REDEMPLO has been reduced from $60,000 to $45,000 per year, aimed at expanding market coverage, particularly for patients with high triglycerides, potentially enhancing market share and competitiveness.
- Strong Financial Position: As of March 31, 2026, Arrowhead reported nearly $1.8 billion in cash and investments, demonstrating robust financial strength to support future R&D and market expansion plans.
- Clinical Trial Progress: Top-line data from the SHASTA-3 and SHASTA-4 studies are expected to be released in Q3, with plans to file a supplemental new drug application with the FDA by the end of 2026, which could provide new growth momentum for the company.
See More
Arrowhead Pharmaceuticals to Participate in Multiple Upcoming Conferences
- Conference Schedule: Arrowhead Pharmaceuticals is set to participate in the BofA Securities 2026 Healthcare Conference from May 12-14, 2026, featuring an investor group dinner and a fireside chat presentation, showcasing its latest advancements in RNA interference.
- Key Presentations: At the TIDES USA conference, Arrowhead will present its systemic RNAi targeting MAPT on May 13 at 4:45 PM, highlighting its potential applications in the central nervous system, which is expected to attract investor interest.
- Clinical Research Showcase: During the European Atherosclerosis Society Congress, Arrowhead will discuss the pharmacokinetics and pharmacodynamics of Plozasiran in subjects with renal or hepatic impairment, underscoring its significance in treating complex diseases.
- Strategic Commitment: Arrowhead's participation not only demonstrates its influence in the global healthcare sector but also indicates its dedication to addressing unmet medical needs through innovative drug development, further solidifying its market position.
See More
Latest Wall Street Rating Updates
- Apple's Positive Outlook: Bank of America reiterates a buy rating on Apple, forecasting that iPhone revenues will exceed expectations in 2026 due to record upgraders and strong gross margins despite commodity pressures, indicating sustained competitiveness in the smartphone market.
- Roblox Demand Slowdown: Bank of America downgrades Roblox to neutral, citing a significant decline in platform demand; while acknowledging its ability to compress development costs, the uncertainty around the timeline for demand recovery may impact its market performance.
- CoreWeave Growth Potential: Citi reiterates CoreWeave as a buy, raising its price target from $126 to $155, estimating a quarterly growth of 35-40% in AI infrastructure, showcasing strong performance across a diversified customer base.
- Hershey's Positive Outlook: TD Cowen upgrades Hershey to buy, expressing confidence that the company will raise its 2026 guidance and return to volume growth in 2027, reflecting strong recovery potential in the confectionery market.
See More
REDEMPLO Approved in Australia for FCS Treatment
- First Approved Drug: REDEMPLO is the first medicine approved in Australia for the treatment of familial chylomicronemia syndrome (FCS), authorized for both genetically confirmed and clinically diagnosed adult patients, marking a significant breakthrough in this therapeutic area.
- Clinical Trial Results: In the Phase 3 PALISADE study, REDEMPLO achieved an 80% median reduction in triglycerides and significantly lowered the incidence of acute pancreatitis, demonstrating its potential to improve patients' quality of life.
- Global Expansion Strategy: This approval follows those in the U.S., Canada, and China, indicating Arrowhead Pharmaceuticals' commitment to expanding global treatment options for FCS patients and enhancing its market competitiveness.
- Innovative Treatment Method: REDEMPLO is administered via self-injection every three months, providing a convenient treatment option that is expected to significantly improve long-term health management and quality of life for FCS patients.
See More
